Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the second quarter ended June 30, 2009.

At June 30, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $13.4 million, as compared to $15.5 million at December 31, 2008. In addition, at June 30, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments. Additionally, in July 2009, the Company received $2.75 million of cash from a settlement with the former licensor of Sulonex (sulodexide). The Company will receive an additional $750,000 on or before July 30, 2010 related to this settlement.

The net income for the second quarter ended June 30, 2009 was $14.1 million, or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the second quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $18.0 million in license revenue relating to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii), which eliminated the Company's significant ongoing obligations included in the original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401, and a $1.0 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008.

The net income for the six months ended June 30, 2009 was $14.6 million, or $0.30 per diluted
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)... , , Vernier,s experience in data analy...orer (TM) program kits and curricula provi...cation ,, BEAVERTON, Ore., Nov. 18 /PRNewswir...r of educational science interfaces, sensors, and ...tional manufacturer and distributor of life scienc...
(Date:11/18/2009)... , , EAST GRINSTEAD, West Sussex, U.K. and...c Systems, a Magellan Biosciences business and pre...lity products for microbiology labs, has expanded ...ch and development facility to meet increasing glo...or susceptibility and identification testing. The ...
(Date:11/18/2009)... , , MISSISSAUGA, ON, Nov. 18 /PRNewswire-F... TSX: YM), a life sciences product development com...lio of promising cancer-related products at variou...om a study evaluating nimotuzumab were presented t...lar Targets and Cancer Therapeutics conference in ...
(Date:11/18/2009)... , , BONITA SPRINGS, Fla., Nov. 18 /PRNe...ect-to-Ethanol® technology, and the technol...te in a joint development project in order to iden...) and oxygen (O2) for Algenol,s unique algae and p...ee the companies join forces to develop cost-effic...
Breaking Biology Technology:Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 2Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 3
..., April 9 /PRNewswire-FirstCall/ - OncoGenex Pharm...ASDAQ: OGXI ), announced today that it has been ...y LifeSciences British Columbia. This annual award...recognize a local organization that has made outst... Columbia,s life sciences industry. This award rec...
... Cell Biosciences, a provider of nanoproteomic an...announced the closing of a $10 million Series C fi...me Trust. Existing investors Domain Associates, L...es, Royal Bank of Canada and The Vertical Group al...y happy to announce this financing in the current ...
... 9 Cepheid (Nasdaq: CPHD ) today announced that...irst quarter ended March 31, 2009, on Thursday, Ap...The company will host a management presentation at...to discuss the results. To access the live webcas....com/investors at least 15 minutes before the sc...
Other Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:11/20/2009)...vember 19, 2009 The estimated 4.6 million America...of developing respiratory symptoms due to poor air...ire study undertaken earlier this year by investig...erinary Medicine. , The studywhich polled more t... percent of individuals working in barns complaine...
(Date:11/20/2009)...le in German . , In the current online issu...Stefanie Eyerich and Dr. Kilian Eyerich together w...and Istituto Dermopatico dell,Immacolata in Rome, ...nts a milestone on the way to developing new treat...s psoriasis and allergic reactions and potentially...
(Date:11/20/2009)...w study, researchers report that a class of heart ...l, or harmful, effect on the heart, depending on t...ars in the journal Circulation Research , found t...beta-receptors on the heart muscle offer the most ...et only the beta-receptors can actually undermine ...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 1Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 2Norway Japan prop up whaling industry with taxpayer money 8913 1Norway Japan prop up whaling industry with taxpayer money 8913 2Burner Balm Joins Forces With Call to the Wall 49440 1
...sons are the Clark Kents of a genome. Apparently m...ursts of activity, these free-floating bits of gen...king into the genetic maps of plants and animals, ...ars, researchers thought that most of this DNA was...ings, however, are peeling back the odd and baffli...
... i.e. substances which can be stimulated to emit ...research and medical diagnosis. Fluorescence can b...expression of genes, to locate proteins in cells a...udy the location and migration of cells. Of partic... imaging with novel techniques that allow tomograp...
...ldstein checks his lobster traps in New Hampshire,... crustaceans to sell. Instead, the University of N...ters with transmitters and tracking their migratio... along the New Hampshire coastline and into Great ...funded by N.H. Sea Grant, will provide more accura...
Other Biology News:New research shows how gene function drives natural selection in important class of genetic elements 2New research shows how gene function drives natural selection in important class of genetic elements 3Novel technique for fluorescence tomography of tumors in living animals 2UNH researchers track lobster migrations to improve population estimates 2UNH researchers track lobster migrations to improve population estimates 3
...us venom Description: Phosphodiesterase I (venom e...d structure and sequence (1) . It hydrolyzes 5'-mo...onucleotides and deoxyribo-oligonucleotides (2) . ...ns at the pyrophosphate linkages to yield phosphor...
Spacer for Miniature FRENCH Pressure Cell from Thermo Scientific
...criptase is a recombinant Moloney murine leukemia ... Reverse Transcriptase is similar to MuLV reverse .... MuLV reverse transcriptase is a recombinant RNA-... RNA as a template in the presence of a primer to ...
...to Prostaglandin F2α (8-iso-13,14-dihydro-1...stane, 8-isoprostane (8-iso PGF2α), in rabb...G-like product of non-specific lipid peroxidation....-isoprostane is converted primarily to metabolites...
Biology Products: